Chronic Systolic Heart Failure, Guideline-Directed Medical Therapy, and Systemic Hypotension-Less Pressure but Maybe More Risk (Does This Clinical Scenario Need More Discussion?)

Wayne L. Miller, Hadi N. Skouri

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Many clinical trials have demonstrated the survival benefit of medication regimens that modulate the neurohormonal activation that occurs with chronic heart failure (HF). These medications, however, also commonly lower systemic blood pressure (BP). Low arterial BP in patients with chronic HF has been shown to be an independent predictor of increased mortality. Given this apparent paradox in therapeutic goals (treat aggressively but keep BP from going too low), how low should we allow systemic BP to go as a result of our medication regimens before we compromise the proven benefits of such drug therapy? Or is the association between the BP-lowering effects of standard therapy and outcomes in HF even meaningful clinically? It is from this perspective that the merits, potential clinical implications, and the relevant published literature pertaining to this patient and practice management issue will be discussed.

Original languageEnglish (US)
Pages (from-to)101-107
Number of pages7
JournalJournal of Cardiac Failure
Volume15
Issue number2
DOIs
StatePublished - Mar 2009

Fingerprint

Systolic Heart Failure
Hypotension
Guidelines
Blood Pressure
Pressure
Heart Failure
Practice Management
Therapeutics
Arterial Pressure
Clinical Trials
Drug Therapy
Survival
Mortality

Keywords

  • guideline-directed medical therapy
  • Heart failure
  • outcomes
  • systemic hypotension

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{3e082d38510042c1997d79a2e1f3971f,
title = "Chronic Systolic Heart Failure, Guideline-Directed Medical Therapy, and Systemic Hypotension-Less Pressure but Maybe More Risk (Does This Clinical Scenario Need More Discussion?)",
abstract = "Many clinical trials have demonstrated the survival benefit of medication regimens that modulate the neurohormonal activation that occurs with chronic heart failure (HF). These medications, however, also commonly lower systemic blood pressure (BP). Low arterial BP in patients with chronic HF has been shown to be an independent predictor of increased mortality. Given this apparent paradox in therapeutic goals (treat aggressively but keep BP from going too low), how low should we allow systemic BP to go as a result of our medication regimens before we compromise the proven benefits of such drug therapy? Or is the association between the BP-lowering effects of standard therapy and outcomes in HF even meaningful clinically? It is from this perspective that the merits, potential clinical implications, and the relevant published literature pertaining to this patient and practice management issue will be discussed.",
keywords = "guideline-directed medical therapy, Heart failure, outcomes, systemic hypotension",
author = "Miller, {Wayne L.} and Skouri, {Hadi N.}",
year = "2009",
month = "3",
doi = "10.1016/j.cardfail.2008.07.228",
language = "English (US)",
volume = "15",
pages = "101--107",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",
number = "2",

}

TY - JOUR

T1 - Chronic Systolic Heart Failure, Guideline-Directed Medical Therapy, and Systemic Hypotension-Less Pressure but Maybe More Risk (Does This Clinical Scenario Need More Discussion?)

AU - Miller, Wayne L.

AU - Skouri, Hadi N.

PY - 2009/3

Y1 - 2009/3

N2 - Many clinical trials have demonstrated the survival benefit of medication regimens that modulate the neurohormonal activation that occurs with chronic heart failure (HF). These medications, however, also commonly lower systemic blood pressure (BP). Low arterial BP in patients with chronic HF has been shown to be an independent predictor of increased mortality. Given this apparent paradox in therapeutic goals (treat aggressively but keep BP from going too low), how low should we allow systemic BP to go as a result of our medication regimens before we compromise the proven benefits of such drug therapy? Or is the association between the BP-lowering effects of standard therapy and outcomes in HF even meaningful clinically? It is from this perspective that the merits, potential clinical implications, and the relevant published literature pertaining to this patient and practice management issue will be discussed.

AB - Many clinical trials have demonstrated the survival benefit of medication regimens that modulate the neurohormonal activation that occurs with chronic heart failure (HF). These medications, however, also commonly lower systemic blood pressure (BP). Low arterial BP in patients with chronic HF has been shown to be an independent predictor of increased mortality. Given this apparent paradox in therapeutic goals (treat aggressively but keep BP from going too low), how low should we allow systemic BP to go as a result of our medication regimens before we compromise the proven benefits of such drug therapy? Or is the association between the BP-lowering effects of standard therapy and outcomes in HF even meaningful clinically? It is from this perspective that the merits, potential clinical implications, and the relevant published literature pertaining to this patient and practice management issue will be discussed.

KW - guideline-directed medical therapy

KW - Heart failure

KW - outcomes

KW - systemic hypotension

UR - http://www.scopus.com/inward/record.url?scp=60849132466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60849132466&partnerID=8YFLogxK

U2 - 10.1016/j.cardfail.2008.07.228

DO - 10.1016/j.cardfail.2008.07.228

M3 - Article

C2 - 19254668

AN - SCOPUS:60849132466

VL - 15

SP - 101

EP - 107

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

SN - 1071-9164

IS - 2

ER -